Research progress of microRNA in gastric cancer

doi:10.3760/cma.j.issn.1673-422X.2015.10.017

Abstract

Dou Yue, Tang Yong. Research progress of microRNA in gastric cancer[J]. Journal of International Oncology, 2015, 42(10): 780-782.

［1］ Shin VY, Chu KM. MiRNA as potential biomarkers and therapeutic targets for gastric cancer［J］. World J Gastroenterol, 2014, 20(30): 10432-10439. ［2］ Halimi M, Asghari SM, Sariri R, et al. Cellular response to ionizing radiation: a microRNA story［J］. Int J Mol Cell Med, 2012, 1(4): 178-184. ［3］ Gao M, Yin H, Fei ZW. et al. Clinical application of microRNA in gastric cancer in Eastern Asian area［J］. World J Gastroenterol, 2013, 19(13): 2019-2027. ［4］ Ren J, Huang HJ, Gong Y, et al. MicroRNA206 suppresses gastric cancer cell growth and metastasis［J］. Cell Biosci, 2014, 4: 26. ［5］ Jia H, Zhang Z, Zou D, et al. MicroRNA10a is downregulated by DNA methylation and functions as a tumor suppressor in gastric cancer cells［J］. PLoS One, 2014, 9(1): e88057. ［6］ Zhao Y, Li C, Wang M, et al. Decrease of miR2023p expression, a novel tumor suppressor, in gastric cancer［J］. PLoS One, 2013, 8(7): e69756. ［7］ Zuo J, Xia J, Ju F, et al. MicroRNA-148a can regulate runtrelated transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer［J］. Mol Cells, 2013, 35(4): 313-319. ［8］ Shen ZY, Zhang ZZ, Liu H, et al. miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression［J］. Exp Ther Med, 2014, 7(6): 1757-1761. ［9］王进, 周建萍, 杨巧媛. 微小RNA98在胃癌中表达下调及其对胃癌细胞生长的调控作用［J］. 中华实验外科杂志, 2013, 30(6): 1245-1247. ［10］ He XJ, Ma YY, Yu S, et al. Upregulated miR199a5p in gastric cancer functions as an oncogene and targets klotho［J］. BMC Cancer, 2014, 14: 218. ［11］王霖沛, 马筱秋, 蔡建春. 微小RNA135b在胃癌发生发展中的临床病理意义及其作用［J］. 中华医学杂志, 2012, 92(46): 32693273. ［12］ Zhao Y, Huang J, Zhang L, et al. MiR133b is frequently decreased in gastric cancer and its overexpression reduces the metastatic potential of gastric cancer cells［J］. BMC Cancer, 2014, 14: 34. ［13］ Chen L, Lü MH, Zhang D, et al. miR12075p and miR1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase［J］. Cell Death Dis, 2014, 5: e1034. ［14］任辉, 任圣男, 金洪水, 等. 微小RNA10b与胃癌转移相关性及对胃癌细胞侵袭迁移能力的影响［J］. 中华普通外科杂志, 2013, 28(2): 153154. ［15］郭玉庆, 张建华, 郭玉双. miR223通过靶定EPB41 L3促进胃癌生长和侵袭的研究［J］. 哈尔滨医科大学学报, 2014, 48(5): 381385. ［16］ ValladaresAyerbes M, Reboredo M, MedinaVillaamil V, et al. Circulating miR200c as a diagnostic and prognostic biomarker for gastric cancer［J］. J Transl Med, 2012, 10: 186. ［17］蔡辉, 袁媛, 韦雪, 等. miR106b、miR20a、miR221在早期胃癌中表达的研究［J］. 中华普通外科杂志, 2014, 29(2): 115118. ［18］ Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers［J］. Expert Rev Mol Med, 2014, 16: e1. ［19］ Yang X, Marcucci K, Anguela X, et al. Preclinical evaluation of an antiHCV miRNA cluster for treatment of HCV infection［J］. Mol Ther, 2013, 21(3): 588601. ［20］ Liu X, Yu H, Cai H, et al. The expression and clinical significance of miR132 in gastric cancer patients［J］. Diagn Pathol, 2014, 9: 57. ［21］刘娟, 史伟峰, 徐斌, 等. 微小RNA129在晚期胃癌组织中的表达及临床意义［J］. 中华消化杂志, 2014, 31(3): 495498. ［22］ Zhang Z, Sun J, Bai Z, et al. microRNA153 acts as a prognostic marker in gastric cancer and its role in cell migration and invasion［J］. Onco Targets Ther, 2015, 8: 357364.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[3]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[6]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[7]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[8]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[9]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185.
[10]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[11]	Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86.
[12]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[13]	Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan. Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer [J]. Journal of International Oncology, 2023, 50(11): 677-682.
[14]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(10): 631-635.
[15]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.

Research progress of microRNA in gastric cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments